Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase…

By H. Kantarjian, F. Giles, N. Gattermann, K. Bhalla, G. Alimena, F. Palandri, G. Ossenkoppele, F. Nicolini, S. O’Brien, M. Litzow and 8 more. Blood, 2007

765 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/425fc436550f680c9e315f164c75517c5ef29d99

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. J. Cortes
2. Andreas Hochhaus
3. H. Kantarjian
4. M. Baccarani
5. Brian J. Druker

In Hematology

1. J. Cortes
2. J. Apperley
3. Andreas Hochhaus
4. J. Goldman
5. H. Kantarjian
6. M. Baccarani
7. Brian J. Druker

In Rheumatology

1. J. Cortes
2. Andreas Hochhaus
3. H. Kantarjian
4. M. Baccarani
5. Brian J. Druker

Citations in the corpus

• A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias (2013, neutral): “Pancreatitis 19 (7) 17 (6) 7 (8) 5 (6) 3 (5) 2 (3) 0 0”
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (2009, background): “For all patients in CP, 1-year OS was 95%, and the proportion of patients remaining in MCgR after 1 year was 96%.(27) In patients in CP, the rate of nilotinib discontinuation for adverse events was 15% overall.”